Puretech presents clinical trial design supporting wholly owned immuno-oncology candidate lyt-200 at the society for immunotherapy of cancer (sitc) 36th annual meeting

Boston--(business wire)--puretech announces a poster presentation of the phase 1/2 clinical trial design supporting wholly owned immuno-oncology candidate lyt-200 at sitc.

PRTC Ratings Summary

PRTC Quant Ranking